Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

President Donald Trump's proposed tariffs on pharmaceuticals could lead to higher prices, higher insurance premiums, and even drug shortages, experts say.

Novartis (NVS) raised its full-year profit outlook thanks to strong demand for some of its key drugs. Novartis CEO Vas ...

Anticipating potential tariffs on South Korean goods, particularly cosmetics, U.S. consumers are stocking up on K-beauty ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

President Trump on Wednesday said he would be sending letters to over 150 countries as he plans a barrage of duties to take ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

By Noreen Marcus, FloridaBulldog.org - Trump’s tariff assault on drug affordability stings a Vero Beach cancer patient ...

Due to concerns surrounding its effectiveness, the US Food and Drug Administration (FDA) ended the Rare Pediatric Disease Designation (RPDD) programme in late 2024.